Prospective application of a multiplex reverse transcription‐polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single‐laboratory study of 390 paediatric and adult patients
- 9 September 2004
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 127 (1) , 59-66
- https://doi.org/10.1111/j.1365-2141.2004.05161.x
Abstract
Summary: The upfront application of molecular methods for identifying the fusion transcripts arising from balanced translocations in haematopoietic malignancies has several advantages: sensitivity is independent of its frequency, i.e. rare ones are not missed, cytogenetically cryptic aberrations are identified and it provides a platform for minimal residual disease (MRD) detection. Employing a multiplex reverse transcription polymerase chain reaction (RT‐PCR) assay identifying 27 fusion transcripts we prospectively analysed blood and/or bone marrow samples from 390 patients referred for diagnosis and treatment for acute leukaemia and chronic myeloproliferative disorders (CMPD) from a geographically well‐defined region in Denmark. A total of 233 patients were diagnosed with acute myeloid leukaemia (AML), 95 with acute lymphoblastic leukaemia (ALL) origin and 62 patients were recorded as CMPD. Twenty‐three percent AML, 32% ALL and 55% CMPD patients exhibited chromosomal aberrations detected by the multiplex RT‐PCR. Cytogenetically cryptic translocations were seen in 15% of the cases. Conversely, the cytogenetic analysis identified chromosomal aberrations other than translocations in 45% of AML cases and 63% of ALL cases. We conclude that, while the fraction of translocation positive leukaemia patients in an unselected cohort is lower than hitherto believed, a molecular approach to their diagnosis is worthwhile, partly for identifying cryptic and rare translocations, partly for monitoring MRD.Keywords
This publication has 26 references indexed in Scilit:
- Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer programLeukemia, 2003
- Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer ProgramLeukemia, 2003
- Translocation t(5;14)(q35;q32) in three cases of childhood T cell acute lymphoblastic leukemia: a new recurring and cryptic abnormalityLeukemia, 2002
- TrueLeukemia, 2001
- Cytogenetically cryptic AML1-ETO and CBFbeta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemiaBritish Journal of Haematology, 2000
- Cytogenetically cryptic AML1-ETO and CBFβ-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemiaBritish Journal of Haematology, 2000
- A Unique Structural Abnormality of Chromosome 16 Resulting in a CBFβ-MYH11 Fusion Transcript in a Patient with Acute Myeloid Leukemia, FAB M4Cancer Genetics and Cytogenetics, 2000
- Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic LeukemiaLeukemia & Lymphoma, 2000
- Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell linesLeukemia, 1997
- Possible pathogenetic significance of specific chromosome abnormalities and activated proto‐oncogenes in malignant diseases of manScandinavian Journal of Haematology, 1986